The 7th Annual Nordic American
Life Science Conference

2022 PARTICIPATING COMPANIES

SWEDEN

BioArctic is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and ALS. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic’s Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B)

Learn more: bioarctic.se

Calliditas is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Calliditas is led by an experienced and dedicated management team with significant prior experience in drug development in the pharmaceutical industry, including at leading companies such as GlaxoSmithKline, Pfizer, and AstraZeneca. The board of directors includes highly qualified executives and experts in drug development, management, operations, and pharmaceutical commercialization.

Learn more: calliditas.se

Palette Life Sciences is a fully integrated life sciences company. Palette Life Sciences’ products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. The company’s portfolio of available products includes Barrigel®, Deflux®, Solesta®, and Lidbree™. Palette Life Sciences moves rapidly to leverage novel applications of existing technologies to create breakthrough medical solutions. This focus enables the company to serve those often overlooked by traditional medical companies and improve patient quality of life. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, Dallas, Texas, Sydney, Australia and Tokyo, Japan.

Find out more at palettelifesciences.com

Founded in 1998, XVIVO is the only medical technology company in the world dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. XVIVO’s solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. The company is the global leader in lung transplantation and the European leader in liver transplantation. A brand-new device for kidney perfusion and transportation has just been launched in the US. Currently, the company runs two multi-center trials for heart preservation in Europe and in Australia/New Zeeland. The launch of this paradigm-shifting heart technology is expected in Q1 2024. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Stockholm Nasdaq.

Learn more: xvivoperfusion.com

Coala Life is a medical device company founded in Sweden. The company develops unique innovations that enable long-term monitoring and remote diagnostics of heart and lungs. The products offer healthcare providers diagnostic support by the ability to follow patient’s in their everyday life.

Since November 2021, Coala Life is publicly traded on Nasdaq First North Stockholm (Nasdaq: COALA.ST). The head office is based in Uppsala, where research and development also takes place. Manufacturing takes place through partners in Finland and Estonia.

Learn more: coalalife.com

NORWAY

Lytix Biopharma is a Phase II clinical-stage drug development company with more than 20 years of preclinical and clinical research. Since June 2021 the company is listed on Euronext Growth.

Lytix has, in collaboration with world-leading cancer research centers, developed a proprietary in situ vaccination technology platform providing a new class of drug candidates for the treatment of cancer. The treatment is aiming for activating the patient’s own immune system to fight cancer.

Learn more: lytixbiopharma.com

Nykode Therapeutics is an Oslo-based clinical-stage biopharmaceutical platform company founded in 2006. Our bold aim is to generate game-changing therapeutics to treat cancers and infectious diseases with a high unmet medical need.

With our unique and innovative modular vaccine technology, we’re specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong, and long-lasting immune responses.

Learn more: nykode.com

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. The company's unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO).

Learn more: photocure.com

Ultimovacs is a Nordic immuno-oncology company with five Phase II randomized clinical combination trials enrolling more than 650 patients in 15 countries. The lead product candidate is UV1, a cancer vaccine inducing a T-cell response against the antigen telomerase which is present in 85-90% of cancer types at all stages. Near-term key value inflection points: Topline readout expected during 1H 2023 for the first two Phase II studies in melanoma and mesothelioma.

Learn more: ultimovacs.com

DENMARK

NMD Pharma is a clinical-stage biotech company founded with a focus to deliver life-transforming therapies for people living with neuromuscular diseases.

Learn more: nmdpharma.com

FINLAND

Faron is a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation. Since founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses.

Learn more: faron.com

Optomed is a leading, global manufacturer of handheld fundus cameras and screening software. Optomed combines its handheld fundus camera with software and artificial intelligence transforming the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy and ophthalmic neurological conditions. Optomed is seen as a quality improvement to ophthalmic emergency medicine. Optomed has offices in Finland, the US, and China. Its products are sold internationally in over 60 countries.

Learn more: optomed.com

ICELAND

Alvotech is a biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East.

Learn more: alvotech.com

Kerecis develops products from fish skin and fatty acids for cellular therapy, tissue regeneration, and protection. When grafted onto damaged human tissue or implanted, the patented material recruits the body’s own cells and ultimately is converted into living tissue. Because no disease-transfer risk exists between cold-water fish and humans, the Kerecis fish skin is only gently processed and retains its similarity to human tissue. The gentle processing preserves the skin’s original three-dimensional structure, maintaining its inherent natural strength, complexity, and molecules (such as fatty acids). Clinical studies have found that Kerecis products heal wounds faster than competing products. Kerecis is the only approved manufacturer of medical devices containing intact fish skin globally.

For more information, visit: kerecis.com

EMERGING COMPANIES SESSION

Abliva aims to become a world leader in mitochondrial medicine, developing therapeutics for patients suffering from mitochondrial diseases, orphan indications of high unmet medical need. Abliva has two programs in development; KL1333 addresses fatigue and myopathy experienced by adults with the disease and will commence a registrational, Phase 2/3 study by the end of the year. NV354 has been designed to treat children with a devastating neurological disease called Leigh syndrome. NV354 has received positive regulatory guidance and is currently preparing for a Phase 1 study. Looking forward, Abliva intends to build a fully integrated research, development, and commercial organization, developing innovative therapeutics and taking them directly to the patients.

For more information, visit abliva.com

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.

The CE-mark-approved and FDA De Novo-cleared Acarix CADScor®System is for patients experiencing chest pain with suspected CAD and is designed to help reduce millions of unnecessary, invasive, costly diagnostic procedures. CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes with 96% confidence.¹

Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

For more information: www.acarix.com

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin®, and Painless.

NeuroRestore is a cognitive enhancer, targeting Alzheimer’s and ready for phase II. Alzstatin is a preventive treatment against Alzheimer’s, currently in preclinical phase. Painless ACD440 is a TRPV1-antagonist against neuropathic pain in phase IIa.

For more information: www.alzecurepharma.se/en/

Anocca is a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for the analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity.

Anocca’s technologies enable the highly precise and efficient analysis of T-cell biology required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas. With a focus on delivering TCR-modified T-cell therapies (TCR-T) in oncology, Anocca is rapidly progressing a pipeline of novel T-cell therapies towards clinical trials utilizing our own manufacturing capabilities.

Anocca’s powerful technologies are also being deployed to develop a range of novel therapeutic and prophylactic products in oncology, infectious disease, and autoimmunity.

For more information: anocca.com

Arctic Bioscience develops products, solutions, and technologies based on bioactive marine compounds that are either kept proprietary or patented. The company is located on the west coast of Norway giving it unique access to the raw material sources and local processing sites. We work closely with selected strategic partners to secure the freshness and quality of our certified raw materials.

Learn more: arctic-bioscience.com

Using healthy human stem cells and cutting edge tissue engineering technologies, ClexBio engineers transplant-ready tissues for patients suffering from severely limiting or life-threatening diseases. The company’s lead asset is a bioengineered transplant-ready vein graft to address chronic venous insufficiency (CVI) - a medical condition impacting millions of patients globally and with no current treatment options.

Learn more: clexbio.com

DoMore Diagnostics is on a mission to transform cancer diagnostics with artificial intelligence to improve patient care and make drug development more effective.

For more information: domorediagnostics.com

Ledidi is a Norwegian software company established in 2016. Ledidi was founded by two academic surgeons and three software engineers with extensive expertise in system architecture, cloud computing, and application design. Based on our research experience in both translational and clinical research within the fields of molecular immunology, cellular biology, oncology and surgery, we have developed the research tool we missed in our own practice. It is our combined expertise that has made it possible to develop an integrated cloud application that is a true end-to-end solution for research projects and registries. Ledidi Core is used by researchers both in Norway and internationally.

For more information: ledidi.com

Medtentia is now called HVR Cardio, a cardiovascular device company is developing breakthrough solutions for mitral valve repair based on its proprietary helix technology. The Company’s lead products, CathHELIX® and MAR®, are transcatheter and surgical mitral valve repair devices that are designed to overcome the debilitating effects of mitral regurgitation or “leaky valve”. Mitral regurgitation is the most common heart valve disorder. It affects 2% of the population and 10% of individuals aged over 75. Mitral regurgitation severely limits physical activity and quality of life and, if left untreated, leads to heart failure and death.

For more information: www.hvrcardio.com

Perfusion imaging provides medical professionals with a functional understanding of the organs’ blood supply inside the patient. MedTrace is developing a solution that will help healthcare providers diagnose patients even more accurately and quickly. The Medtrace solution allows for absolute blood flow quantification based upon the PET tracer 15O-water, which has long been acknowledged as the gold standard tracer for perfusion imaging.

For more information: medtrace.dk

PainDrainer is a digital pain coach, powered by artificial intelligence, that discovers how your activities affect your pain. Based on your own data, the app guides and gives you personal advice and suggestions on how to plan your day. This will help you find the activity balance that suits you to control your pain.

With PainDrainer as your coach, you will have energy for activities that are most valuable to you.

Learn more: paindrainer.com

StemSight's founding team has worked with novel biomaterial solutions for ophthalmic applications and culture and differentiation methods for human induced pluripotent stem cells (hiPSC) for several years. Building on this experience, StemSight is developing new cell therapy products for the treatment of blindness.

Learn more: stemsight.fi

Finnadvance's AKITA Organ-on-Chip platform is designed to mimic key microphysiological conditions of certain biological structures such as the Blood-Brain-Barrier, while maintaining the highest throughput on the markets. Finnadvance platform is replacing current suboptimal research methods that produce unreliable data and cause over 90% of all new pharmaceuticals to fail in clinical trials and close to 100% with central nervous system-related compounds. Finnadvance products help pharmaceutical industry to find ways and new molecules that will cross the blood-brain-barrier or other biological barriers and ensure better results in clinical trials.

Learn more: finnadvance.com